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with bicuspid aortic valves excluded from
the study? Did patients with Gothic arches
and bicuspid valves have even greater
changes? Did any of the patients with
Gothic arch and a tricuspid aortic valve
have aortic insufficiency or require valve
replacement/repair?
Approximately 15% of patients who are
status-post repair of type I aortic dissection
require replacement of the proximal de-
scending aortic owing to increasing diame-
ter on long-term follow-up. It has also
been my impression that those patients
who have repair of type I aortic dissection
with replacement of the ascending aorta
and hemiarch repair have a greater incidence
of progressive aortic insufficiency and may
require aortic valve replacement or aortic
root replacement. This cohort is in contrast
to those patients with type I aortic dissection
who simply had ascending aortic replace-
ment and appeared to have a lesser inci-
dence of aortic insufficiency and valve or
root replacement over the long term.
Might the hemodynamic changes that
were documented in the pediatric angular
Gothic arch be present in this status-post
aortic dissection group and predispose to
aortic valve insufficiency and dilation of
the proximal portion of the distal descend-
ing thoracic aorta? Might this effect be
more pronounced in the hemiarch repair
that predisposes to an angular Gothic arch
configuration? Replacement of the ascend-
ing aorta only (without hemiarch repair)
usually preserves the concave configura-
tion of the ascending aorta and its gentle
curve into the transverse arch. Ascending
aorta and hemiarch replacement typically
has an angulated Gothic configuration
rather than the gentle curve that nature
favors.
Frank A. Baciewicz, Jr, MD
Professor of Cardiothoracic Surgery
Wayne State University
School of Medicine
Detroit, MI 48201
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Aprotinin and renal dysfunction:
The role of exposure to
angiotensin-converting enzyme
inhibitors
To the Editor:
I read with great interest the recent article by
Pagano and colleagues1 detailing their fa-
vorable experience with aprotinin in a large
patient series (N 5 7836: 1998–2006) from
a single institution. The authors demon-
strated that aprotinin exposure did not
significantly affect the incidence of postop-
erative renal dysfunction.
Careful review of this interesting paper re-
veals, however, that although hypertension
was significantly more common in the aproti-
nin cohort (63.3% vs 55.1%; P , .001), the
incidenceof exposure to angiotensin-convert-
ing enzyme (ACE) inhibitors is not indicated.
This is an important confounder, inasmuch as
ACE inhibitors in conjunction with aprotinin
have been shown to be associated with renal
dysfunction after cardiac surgery.2,3
As a consequence of this observation, I
have the following questions:
1. What was the incidence of ACE
inhibitor therapy in the aprotinin
cohort?
2. Was exposure to ACE inhibitors sig-
nificantly different in the aprotinin
cohort?
3. What was the percentage of off-pump
coronary bypass procedures, given
that aprotinin and ACE inhibitors
have recently been significantly asso-
ciated with postoperative renal dys-
function in this patient subgroup?3
4. Could the incidence ofACE inhibitor
exposure have confounded the re-
sults of the study, given the findings
from the literature?2,3 For example,
could a lack of renal toxicity from
aprotinin be explained by a low inci-
dence of exposure to ACE inhibitors
in the aprotinin cohort?
I congratulate the authors again on their
important contribution. I look forward to
their feedback about the impact of ACE
exposure and aprotinin on renal dysfunction
after cardiac surgery.
John G. T. Augoustides, MD, FASE
Associate Professor
Department of Anesthesiology and Critical Care
Hospital of the University of Pennsylvania
Philadelphia, PA 19104-4283
Financial support: Department of Anesthesiology
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Dr Augoustides raises an appropriate point.
It is the policy in our unit to discontinue
angiotensin-converting enzyme inhibitors
or equivalents 24 hours before the operation
and for patients with impaired renal func-
tion, at least 48 hours before the operation.
However our database does not have infor-
mation on compliance to this policy. There-
fore, we could not address this issue in our
article.1
Domenico Pagano, MD, FRCS, FESC
Department of Cardiothoracic Surgery
University Hospital Birmingham
Edgbaston
Birmingham, West Midlands, United Kingdom
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regimen of treatment with low-
dose and longer-course using
recombinant tissue-type
plasminogen activator is
a promising protocol
To the Editor:
Despite the progress in anesthesia, cardiac
surgery, and perioperative care, the thera-
peutic decision in prosthetic valve thrombo-
sis (PVT) remains in discussion.
In recent years thrombolytic therapy has
won acceptance, and for many it is the first
